What are people hoping for. I've included my base case where anything above I think would be good, and anything
- Q4 revenue ($93m) and CY2024 revenue ($345m) (Midpoint)
- CY2025 guidance: North American Daybue Revenue 400bn+ (15%+)
I think a slightly lower figure for Q4 may be okay provided the guidance/outlook is positive. I think a result of <91m for Q4 paired with a <370m for the full year 2025 could be poorly taken. I think a positive suprise would be >$93m for Q4 and >$400m for 2025 Daybue sales. 400m sales for Daybue is 15% growth in North America which might not seem like much but given Acadia's 1bn+ sales revenue and the analyst expectation of 1.05bn there's no positive expectations baked in at all, given Nuplazid is at a $600bn run rate and even if it grows 5% (630m) that only leaves 370m+ sales of Daybue to get to 1bn+ which is 7.25% YoY growth. Let's hope Acadia are internally looking for 1bn+ but aiming for 1.1m~ revenue for the full year combined Daybue and Nupazlid.
- Forums
- ASX - By Stock
- NEU
- Acadia
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.69%
!
$14.20

Acadia, page-1341
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B |
Open | High | Low | Value | Volume |
$13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | $14.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.23 | 3278 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 14.170 |
2 | 1626 | 14.160 |
1 | 1000 | 14.100 |
2 | 2963 | 14.030 |
3 | 2000 | 14.000 |
Price($) | Vol. | No. |
---|---|---|
14.230 | 3278 | 1 |
14.250 | 2027 | 3 |
14.260 | 2920 | 1 |
14.270 | 1191 | 1 |
14.300 | 1163 | 2 |
Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online